<DOC>
	<DOCNO>NCT00701597</DOCNO>
	<brief_summary>Several line evidence suggest ocular perfusion abnormality may contribute progression glaucoma . It hypothesise increase endothelin-1 plasma level , see patient glaucoma , may relate alteration ocular blood flow . We could show recent experiment administration ET-1 decrease ocular blood flow , whereas block ET-A receptor affect basal vascular tone healthy subject . In current study set evaluate effect Bosentan , non-selective ETA-receptor antagonist patient open-angle glaucoma . This allow u test hypothesis administration ET-1 receptor antagonist increase ocular blood flow patient glaucoma . Investigations do retinal vessel analyzer determine retinal vessel cross-sectional diameter , laser Doppler flowmetry laser Doppler velocimetry determine subfoveal macular blood flow optic nerve head blood flow laser interferometric measurement determine fundus pulsation amplitude macula . The intraocular pressure measure applanation tonometry . This assessed baseline response peroral application Bosentan placebo . The study objective therefor , evaluate contribution ET-1 ocular blood flow dysregulation patient open-angle glaucoma .</brief_summary>
	<brief_title>Effects Non-Specific Endothelin-A Receptor Blockade Ocular Blood Flow Patients With Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Inclusion Criteria Men woman age 18 year Normal finding medical history physical examination unless investigator considers abnormality clinically irrelevant Inclusion criterion patient primary open angle glaucoma define pathological optic disc appearance characteristic visual field loss Men woman include equal part Ametropia le 6 diopter anisometropia less 2 diopter Exclusion Criteria ( glaucoma patient ) Abuse alcoholic beverage , participation clinical trial 3 week precede study Smoking Symptoms clinically relevant illness 3 week first study day History presence gastrointestinal , liver kidney disease , condition know interfere distribution , metabolism excretion study drug Elevated liver enzymes AST ALT Blood donation previous 3 week Ametropy 6 dpt Systemic treatment , oral antikoagulation , Glibenclamid vasoactive drug History IOP &gt; 30 ( untreated ) Presence intraocular pathology glaucoma Advanced visual field defect define MD &gt; 10 Presence PEX ( pseudoexfoliation ) glaucoma pigment glaucoma Ophthalmolgical surgery ( include argon laser trabeculoplasty ( ALT ) , trabeculectomy , deep sclerectomy ) within last 6 month study Pregnancy Diabetes mellitus Exclusion criterion ( healthy control ) Abuse alcoholic beverage , participation clinical trial 3 week precede study Smoking Symptoms clinically relevant illness 3 week first study day History presence gastrointestinal , liver kidney disease , condition know interfere distribution , metabolism excretion study drug Blood donation previous 3 week Ametropy 6 dpt Systemic treatment oral anticoagulation , Glibenclamid vasoactive drug Elevated liver enzymes AST ALT Pregnancy Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ocular blood flow dysregulation , glaucoma , endothelin-1</keyword>
</DOC>